The researchers concluded that the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-05280586 and the reference were similar at the conclusion of the study at week 26.
In a study to be presented at the American Society of Hematology’s annual meeting held in San Diego, California from December 1-4, 2018, researchers evaluated PF-05280586, a proposed rituximab biosimilar, versus the EU-licensed reference product, MabThera, in patients with previously untreated CD20-positive, low tumor burden follicular lymphoma.
"If approved this may help provide a more cost-effective treatment option and expand access for patients and physicians," said Jeff Sharman, MD, medical director, US Oncology Hematology Research.
The 52-week comparative study investigated the efficacy, safety, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-05280586 compared with the reference. In total, 394 patients enrolled in the study and were randomized to receive either PF-05280586 (n = 196) or the reference (n = 198).
The primary end point of the study was overall response rate (ORR) at week 26, defined as the percentage of patients achieving complete response (CR) or partial response (PR) based on central review. Secondary end points included progression free survival, safety, immunogenicity, PK and PD.
Overall, the study found that ORR at week 26 was 75.5% in the PF-05280586 arm, compared with 70.7% in the reference arm, for a difference of 4.66%. The corresponding 95% CI, —4.16 to 13.47, was within the prespecified equivalence margin of ±16%.
At week 26, 11.5% of patients in the potential biosimilar arm had stable disease, compared with 19.6% in the reference. Additionally, 3.4% versus 4.3% had progressive disease in the PF-05280586 group versus the reference group, respectively.
The researchers found that the incidence of treatment-emergent adverse events (TEAEs) was similar, with 78.6% for PF-05280586 versus 72.1% for the reference. The most frequently reported TEAEs were infusion-related reactions (25.5% versus 29.9%), pruritus (6.6% versus 11.2%), and headache (8.2% versus 9.6%) in the PF-05280586 and the reference groups, respectively.
The most frequently reported grade 3 TEAEs were infusion-related reactions and hypertension, seen in 2.6% versus 0.5% and 1.0% versus 2.0% in the PF-05280586 group versus the reference group.
The researchers concluded that the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-05280586 and the reference were similar at the conclusion of the study at week 26.
"With a patient centered approach and over a decade of experience globally. Pfizer remains dedicated to developing and delivering high quality biosimilars with similar efficacy and safety profiles to originator medicines that help have a meaningful impact on people living with various conditions including cancer," said Joe McClellan, vice president of biosimilars development at Pfizer, in announcing the results.
Reference
Sharman J, Liberati A, Silva R, et al. A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL). Presented at the American Society of Hematology Annual Meeting, December 1-4, 2018; San Diego, California. Abstract 394. ash.confex.com/ash/2018/webprogram/Paper111248.html.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.